GlaxoSmithKline (United Kingdom)-ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2013

  1. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-Week results of the VIKING study

    Journal of Infectious Diseases, Vol. 207, Núm. 5, pp. 740-748

2011

  1. European recommendations for the clinical use of HIV drug resistance testing: 2011 update

    AIDS Reviews, Vol. 13, Núm. 2, pp. 77-108

2009

  1. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): A randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance

    Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 398-410

2004

  1. Updated European recommendations for the clinical use of HIV drug resistance testing

    Antiviral Therapy, Vol. 9, Núm. 6, pp. 829-848